Identifying drivers of first-line HR+/HER2- metastatic breast cancer treatment choices.
Adam M BrufskyMartine C MaculaitisLewis KopenhaferPatrick OlsenSamantha K KuroskyLillian Shahied ArrudaWendy HeckAshley S Cha-SilvaPublished in: Future oncology (London, England) (2024)
Aim : Assess factors associated with first-line (1L) treatment for HR+/HER2- metastatic breast cancer. Materials & methods : A cross-sectional survey of 250 US oncologists was conducted. Correlations were calculated between treatment class and demographics, treatment perceptions and other clinical/nonclinical characteristics. Results : Efficacy and safety/tolerability were critical in oncologists' 1L decision-making. CDK4/6i use positively correlated with proportion of Medicare and postmenopausal patients (r = 0.54-0.67). Chemotherapy use demonstrated positive correlations with perimenopausal and premenopausal patients and symptom burden (r = 0.31-0.42). Aromatase inhibitor (AI) monotherapy correlated positively with anticipated treatment compliance (r = 0.42). Conclusion : Efficacy and safety/tolerability were most important to 1L decision-making. Clinical characteristics corresponded with CDK4/6i and chemotherapy use. Anticipated compliance was associated with AI monotherapy use.
Keyphrases
- end stage renal disease
- decision making
- combination therapy
- small cell lung cancer
- newly diagnosed
- ejection fraction
- open label
- squamous cell carcinoma
- primary care
- metastatic breast cancer
- clinical trial
- randomized controlled trial
- prognostic factors
- artificial intelligence
- peritoneal dialysis
- patient reported outcomes
- radiation therapy
- replacement therapy
- body composition
- locally advanced
- deep learning
- bone mineral density
- palliative care
- patient reported
- double blind
- affordable care act